Biosynth Appoints Matt Gunnison as CEO, Kieran Murphy as Chairman in Leadership Reshuffle

Biosynth, a global provider of essential raw materials and services to the life sciences industry, has named Matt Gunnison as its new Chief Executive Officer and appointed him to the Board of Directors, effective immediately. Kieran Murphy has also been appointed Chairman, with both leadership changes taking effect today. Gunnison steps into the role following Urs Spitz, who led Biosynth through a period of impressive growth, solidifying its role in the life sciences market. Spitz will continue to serve on the Board of Directors, supporting the company’s ongoing mission and vision.

Kugan Sathiyanandarajah, Partner at KKR and Head of Europe for KKR’s Health Care Strategic Growth strategy, said in a statement, “We are grateful to Urs for his significant contributions in shaping Biosynth into the innovative and thriving company it is today. We are now excited to welcome Matt as CEO, whose vision and extensive experience will be pivotal in leading the company through its next chapter.” 

Matt Gunnison, also added, “I am thrilled to join Biosynth at such an exciting time in its journey. The company has built a strong foundation under Urs’s leadership, and I look forward to working with the talented team to further accelerate our growth and innovation. Together, we will continue to deliver critical raw materials and services that drive advancements in the life sciences and make a real impact on global health outcomes.”

Matt Gunnison, who co-founded Gamma Biosciences, a life sciences investment platform backed by KKR, currently serves as its CEO. With nearly 20 years of experience in healthcare and life sciences, Matt has led the acquisition and management of growth-stage companies in the biopharmaceutical manufacturing sector. Before his tenure at Gamma, he held multiple leadership roles at GE Healthcare, including heading corporate development for its $19B division. Matt holds a B.A. in Economics from Georgetown University and a J.D. from the University of Michigan.

“It’s a privilege to be appointed Chairman of Biosynth. I am excited to work alongside Matt and the entire team as we chart the course for the company’s continued growth. Biosynth is at the forefront of innovation in the life sciences industry, and I am confident we have the right leadership and vision to drive our success forward,” mentioned Kieran Murphy.

“I’m immensely proud of what Biosynth has accomplished. I would like to congratulate Matt and Kieran on their new roles and wish them, along with the whole Biosynth team, great success in the years ahead. I look forward to continuing to support them in my role on the Board as they lead Biosynth into this new chapter,” commented Urs Spitz.

Kieran Murphy, a senior advisor to KKR, will join Biosynth as Chairman. Kieran brings extensive leadership experience in healthcare and life sciences, including his role as former President and CEO of GE Healthcare and GE Healthcare Life Sciences. He has served as Chairman of Gamma Biosciences since 2022. Additionally, Eric Simpson, formerly Vice President at Gamma Biosciences, will take on the role of Head of Corporate Development at Biosynth.